xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion
Fructose-rich diets (FRD) produces metabolic disturbances characteristic of metabolic syndrome (MS), which leads to non-alcoholic fatty liver disease (NAFLD). Our purpose was to evaluate the effect of co-administration of metformin (Met) plus naringin (NAR) on systemic and metabolic alterations lead...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2023
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/42644 |
| Aporte de: |
| id |
I10-R327-article-42644 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
Fructose rich diet Metabolic Syndrome Non alcoholic fatty liver disease metformin, naringin Dieta rica en fructosa Síndrome metabólico Enfermedad del Hígado Graso No Alcohólico metformina, naringina |
| spellingShingle |
Fructose rich diet Metabolic Syndrome Non alcoholic fatty liver disease metformin, naringin Dieta rica en fructosa Síndrome metabólico Enfermedad del Hígado Graso No Alcohólico metformina, naringina Rizzi MA, MA Mazo, TM Tolosa de Talamoni , NG Rodríguez , VA xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion |
| topic_facet |
Fructose rich diet Metabolic Syndrome Non alcoholic fatty liver disease metformin, naringin Dieta rica en fructosa Síndrome metabólico Enfermedad del Hígado Graso No Alcohólico metformina, naringina |
| author |
Rizzi MA, MA Mazo, TM Tolosa de Talamoni , NG Rodríguez , VA |
| author_facet |
Rizzi MA, MA Mazo, TM Tolosa de Talamoni , NG Rodríguez , VA |
| author_sort |
Rizzi MA, MA |
| title |
xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion |
| title_short |
xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion |
| title_full |
xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion |
| title_fullStr |
xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion |
| title_full_unstemmed |
xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion |
| title_sort |
xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion |
| description |
Fructose-rich diets (FRD) produces metabolic disturbances characteristic of metabolic syndrome (MS), which leads to non-alcoholic fatty liver disease (NAFLD). Our purpose was to evaluate the effect of co-administration of metformin (Met) plus naringin (NAR) on systemic and metabolic alterations leading to NAFLD in animals with MS.
Male Wistar rats were divided in 5 groups: 1) controls (C); 2) FRD 10% (w/v) in drinking water, 60 days; 3) FRD+Met (100 mg/kg b.w.); 4) FRD+NAR (40 mg/kg b.w.); 5) FRD+Met+NAR. Treatments started on day 21 of FRD administration. Biometric, serum biochemical and liver structure parameters were measured. Fatty acid (FA) profile and gene expression of acetyl COA carboxylase (ACAC) and stearoyl-CoA desaturase 1 (SCD1) were determined in the liver. ANOVA/Bonferroni (p<0.05) was used for statistical analysis.
Body weight and waist circumference were significantly higher in FRD rats compared to C rats. All treatments decreased waist circumference. Adiposity, hepatosomatic index, and epididymal fat increased in FRD animals, effects that were reversed with Met+NAR. FRD animals had higher levels of TG/HDL ratio, AST, and LDH enzyme activities; NAR and combined treatment reduced these parameters. Also, liver fibrosis was attenuated by Met+NAR. Palmitic acid, monounsaturated FA and ω6/ω3 ratio were higher in FRD rats compared to C rats, while Met+NAR improved these parameters. ACAC and SCD1 gene expression increased in FRD rats compared to C group and decreased with the treatments.
In conclusion, Met+NAR could be used as a new therapeutic alternative for the treatment of NAFLD, as it reverses biochemical and histological alterations and liver fibrosis, altered in this pathology. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2023 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/42644 |
| work_keys_str_mv |
AT rizzimama xperimentalfructoseinducednonalcoholicfattyliverdiseasemetforminandnaringinreversion AT mazotm xperimentalfructoseinducednonalcoholicfattyliverdiseasemetforminandnaringinreversion AT tolosadetalamoning xperimentalfructoseinducednonalcoholicfattyliverdiseasemetforminandnaringinreversion AT rodriguezva xperimentalfructoseinducednonalcoholicfattyliverdiseasemetforminandnaringinreversion AT rizzimama enfermedaddelhigadograsonoalcoholicoexperimentalinducidaporfructosareversionconmetforminaynaringina AT mazotm enfermedaddelhigadograsonoalcoholicoexperimentalinducidaporfructosareversionconmetforminaynaringina AT tolosadetalamoning enfermedaddelhigadograsonoalcoholicoexperimentalinducidaporfructosareversionconmetforminaynaringina AT rodriguezva enfermedaddelhigadograsonoalcoholicoexperimentalinducidaporfructosareversionconmetforminaynaringina |
| first_indexed |
2024-09-03T21:04:40Z |
| last_indexed |
2024-09-03T21:04:40Z |
| _version_ |
1809210388505427968 |
| spelling |
I10-R327-article-426442023-10-19T21:20:27Z xperimental fructose-induced non alcoholic fatty liver disease: metformin and naringin reversion Enfermedad del hígado graso no alcohólico experimental inducida por fructosa: reversión con metformina y naringina Rizzi MA, MA Mazo, TM Tolosa de Talamoni , NG Rodríguez , VA Fructose rich diet Metabolic Syndrome Non alcoholic fatty liver disease metformin, naringin Dieta rica en fructosa Síndrome metabólico Enfermedad del Hígado Graso No Alcohólico metformina, naringina Fructose-rich diets (FRD) produces metabolic disturbances characteristic of metabolic syndrome (MS), which leads to non-alcoholic fatty liver disease (NAFLD). Our purpose was to evaluate the effect of co-administration of metformin (Met) plus naringin (NAR) on systemic and metabolic alterations leading to NAFLD in animals with MS. Male Wistar rats were divided in 5 groups: 1) controls (C); 2) FRD 10% (w/v) in drinking water, 60 days; 3) FRD+Met (100 mg/kg b.w.); 4) FRD+NAR (40 mg/kg b.w.); 5) FRD+Met+NAR. Treatments started on day 21 of FRD administration. Biometric, serum biochemical and liver structure parameters were measured. Fatty acid (FA) profile and gene expression of acetyl COA carboxylase (ACAC) and stearoyl-CoA desaturase 1 (SCD1) were determined in the liver. ANOVA/Bonferroni (p<0.05) was used for statistical analysis. Body weight and waist circumference were significantly higher in FRD rats compared to C rats. All treatments decreased waist circumference. Adiposity, hepatosomatic index, and epididymal fat increased in FRD animals, effects that were reversed with Met+NAR. FRD animals had higher levels of TG/HDL ratio, AST, and LDH enzyme activities; NAR and combined treatment reduced these parameters. Also, liver fibrosis was attenuated by Met+NAR. Palmitic acid, monounsaturated FA and ω6/ω3 ratio were higher in FRD rats compared to C rats, while Met+NAR improved these parameters. ACAC and SCD1 gene expression increased in FRD rats compared to C group and decreased with the treatments. In conclusion, Met+NAR could be used as a new therapeutic alternative for the treatment of NAFLD, as it reverses biochemical and histological alterations and liver fibrosis, altered in this pathology. Una dieta rica en fructosa (DRF) produce perturbaciones metabólicas características del síndrome metabólico (SM), el cual conlleva a la enfermedad del hígado graso no alcohólico (EHGNA). El objetivo fue evaluar el efecto de la administración conjunta de metformina (Met) + naringina (NAR) sobre las alteraciones hepáticas y metabólicas sistémicas que llevan a la EHGNA en animales con SM. Ratas Wistar machos adultas se dividieron en 5 grupos (n=6 por grupo): 1) controles; 2) alimentadas con DRF (10% P/V) durante 60 días; 3) DRF+Met (100 mg/kg p.c.); 4) DRF+NAR (40 mg/kg p.c.); 5) DRF+Met+NAR. Los tratamientos se iniciaron el día 21 de la administración de DRF hasta 60 días. Se midieron parámetros biométricos, bioquímicos séricos y de estructura hepática. En hígado se determinó el perfil de ácidos grasos y la expresión génica de acetil COA carboxilasa (ACAC) y estearoil-CoA desaturasa 1 (SCD1). Se empleó ANOVA/Bonferroni (p<0,05). El peso corporal y circunferencia de cintura de ratas DRF fueron mayores que los del control; los tratamientos normalizaron el último parámetro. Índice hepatosómico y de adiposidad y la grasa epididimal aumentaron en animales DRF en comparación con los de los controles, efectos que se revirtieron con Met+NAR. Ratas DRF presentaron mayor relación TG/HDL y de las actividades enzimáticas de aspartato aminotransferasa (AST) y lactato deshidrogenasa (LDH), en comparación con los de los controles; el tratamiento con NAR y el combinado redujeron dichos parámetros. La histología hepática del grupo DRF reveló dilatación del espacio portal mientras que los tratamientos la disminuyeron. Ratas DRF presentaron fibrosis hepática (9,9%) en comparación al control (0,65%), mientras que Met+NAR la revirtió (0,31%). La concentración de ácido palmítico fue mayor en DRF en comparación al control y Met+NAR la revirtió (C:44,72±0,91; DRF:51,76±1,22*; DRF+Met:52,99±1,51*; DRF+NAR:53,53±1,26*; DRF+Met+NAR: 46,76±1,09+×; *p<0,01 vs Control; +p<0,01 vs DRF; ×p<0,01 vs DRF+Met y DRF+NAR). La expresión génica de ACAC y SCD1 aumentó en ratas DRF en comparación con el control y disminuyó con los tratamientos. En conclusión, Met+NAR podría utilizarse como una nueva alternativa terapéutica para el tratamiento de EHGNA, ya que revierte los parámetros bioquímicos, las alteraciones histológicas y la fibrosis hepática. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2023-10-19 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/42644 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 80 (2023): Suplemento JIC XXIV Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 80 (2023): Suplemento JIC XXIV Revista da Faculdade de Ciências Médicas de Córdoba; v. 80 (2023): Suplemento JIC XXIV 1853-0605 0014-6722 spa https://revistas.unc.edu.ar/index.php/med/article/view/42644/42848 Derechos de autor 2023 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |